32 results about "Pharmacokinetic analysis" patented technology

A method for performing a high-resolution pharmacokinetic analysis for calculation of tissue parameters for a fast-enhancing tissue enables medical personnel to accurately determine pharmacokinetic parameters in fast-enhancing tissues. The method includes obtaining mask image data of the tissue when it is in a steady state condition, obtaining a time series of image data of the tissue when the contrast agent is flowing in the tissue, and increasing a spatial resolution of the time series of image data using the mask image data to obtain a time series of increased spatial resolution image data. The method further includes performing a pharmacokinetic analysis to obtain data including at least one parameter that characterizes the tissue, providing a multi-parameter look-up table derived from a combination of two or more parameters, and providing a display including one parameter or a parametric image, where the parametric image is derived from the look-up table.

Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and / or prognostic factors.

The method and apparatus rapidly separate drugs and their metabolites from saliva and, in a continuous sequence of steps, rapidly detect, identify and quantify them through surface-enhanced Raman spectroscopy.

A method for pharmacokinetic analysis, including: receiving time-series medical image data of a patient introduced with a contrast agent; identifying a reference region in the medical image data; identifying a plurality of points of interest in the medical image data; measuring an intensity of voxels in the reference region; and for each point of interest, measure an intensity of voxels therein, use the measured reference region and point of interest intensities to obtain an expression relating the point of interest's voxel concentration to that of the reference region, wherein the expression is a five-parameter nonlinear model with no reference to an arterial input function; and obtain values for each of the five-parameters by solving the expression and use the obtained values to determine whether the point of interest is malignant.

The invention belongs to the technical field of pharmacokinetic analysis, and relates to an HPLC analysis method for simultaneously measuring the concentrations of curcumin and 5-fluorouracil in animal plasma. The initial steps include the preparation of standard solution, sample pretreatment, sample separation, detection of sample peak area and preparation of standard curve. The method overcomes the difficulty that curcumin and 5-fluorouracil are greatly different in polarity and is not easily eluted and separated in the same chromatographic system, and can simultaneously determine the concentrations of curcumin and 5-fluorouracil in plasma.

The invention provides a detection antibody, application and detection method of an anti-VEGFR-2 monoclonal antibody. The detection antibody includes a heavy chain variable region and a light chain variable region, and the amino acid sequence of the heavy chain variable region is selected from SEQ. ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8; the amino acid sequence of the light chain variable region is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 or SEQ ID NO:12. The present invention has screened a detection antibody against anti-VEGFR-2 monoclonal antibody, which can quickly, sensitively and accurately detect the drug concentration of anti-VEGFR-2 monoclonal antibody in body fluids, in order to assist the detection of anti-VEGFR-2 The pharmacology and pharmacokinetic analysis of monoclonal antibody clinical diagnosis and clinical trials provide reliable research methods.

The invention discloses a method for detecting the concentration of ticagrelor and its active metabolites in human plasma, which comprises the following steps: (1) preparation of a standard working solution; (2) sample processing; (3) preparation of a standard curve; 4) Quantitative analysis: take the test sample and process it according to the method of step (2), and calculate according to the standard curve equation obtained in step (3), to obtain the concentration of ticagrelor and its active metabolite in the sample to be tested. The present invention uses high-performance liquid chromatography (HPLC) to measure the concentration of ticagrelor and its active metabolites in human plasma, and accurately quantifies the concentration of ticagrelor and its active metabolites in human plasma. Reasonable selection of methods, mobile phases, mass spectrometry conditions, etc., optimization of experimental conditions such as flow rate, mobile phase ratio, and chromatographic conditions, etc. After a series of methodological verifications, the entire quantitative detection method is practical, easy to operate, high in repeatability, and good in accuracy , strong operability, and can be directly applied to the detection and analysis of plasma samples of clinical patients and related pharmacokinetic analysis.